With respect to clinical relevance, a recent study showed no impact of moderately higher NAb titers (pre-existing titers up to 340) on the transduction efficiency or efficacy of an intravenous delivery of an anti-AAV5 human factor IX gene therapy in a phase IIb trial for treatment of Hemophilia B [30]. The gene discussed is F9; the disease is hemophilia B.